KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Net Cash Flow (2019 - 2025)

GoodRx Holdings' Net Cash Flow history spans 7 years, with the latest figure at -$11.7 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 147.66% year-over-year to -$11.7 million; the TTM value through Dec 2025 reached -$186.5 million, up 16.71%, while the annual FY2025 figure was -$186.5 million, 16.71% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$11.7 million at GoodRx Holdings, down from -$7.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $32.9 million in Q3 2023 and bottomed at -$147.4 million in Q1 2025.
  • The 5-year median for Net Cash Flow is -$8.1 million (2024), against an average of -$35.5 million.
  • The largest annual shift saw Net Cash Flow surged 1976.68% in 2023 before it tumbled 3655.01% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $29.1 million in 2021, then fell by 2.43% to $28.4 million in 2022, then crashed by 532.04% to -$122.6 million in 2023, then soared by 120.04% to $24.6 million in 2024, then crashed by 147.66% to -$11.7 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Net Cash Flow are -$11.7 million (Q4 2025), -$7.8 million (Q3 2025), and -$19.7 million (Q2 2025).